106 filings
8-K
APVO
Aptevo Therapeutics Inc
15 Apr 24
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4:17pm
8-K
APVO
Aptevo Therapeutics Inc
7 Mar 24
Other Events
8:56am
8-K
APVO
Aptevo Therapeutics Inc
5 Mar 24
Amendments to Articles of Incorporation or Bylaws
5:05pm
8-K
APVO
Aptevo Therapeutics Inc
5 Mar 24
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
8:15am
8-K
APVO
Aptevo Therapeutics Inc
6 Feb 24
Submission of Matters to a Vote of Security Holders
4:37pm
8-K
uxb1x0oiezm7md1o6g
14 Nov 23
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
12:00am
8-K
be1ktu2f
9 Nov 23
Entry into a Material Definitive Agreement
5:17pm
8-K
zii5w58f1qz
3 Nov 23
Entry into a Material Definitive Agreement
4:15pm
8-K
8abi94eep1r8e1
15 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
thrub
10 Aug 23
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
8:16am
8-K
pfj9nkk8op8rht2gdvt
4 Aug 23
Entry into a Material Definitive Agreement
6:51pm
8-K
5xnc5 prs5
18 Jul 23
Aptevo Announces Positive Duration of Remission Data
8:16am
8-K
4b3kegx8ovhoob3
2 Jun 23
Submission of Matters to a Vote of Security Holders
4:28pm
8-K
v2v5m7uy
11 May 23
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
8:15am
8-K
qvjwl8mqn7s
30 Mar 23
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
7:50am
8-K
rvhg6yjm2h461n
30 Mar 23
Entry into a Material Definitive Agreement
7:40am
8-K
3mgi2 kvicr
7 Mar 23
Departure of Directors or Certain Officers
8:15am
8-K
q0wj9
13 Feb 23
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
8:15am
8-K
rnnjf2na7x4xw
9 Jan 23
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
8:15am
8-K
g3eh 85ec
12 Dec 22
Other Events
8:17am